...Health info at your doorstep

Day: 4 March 2021

Rotavirus vaccines made available for use in humanitarian crises

Rotavirus vaccines made available for use in humanitarian crises

NEWS
  Health partners welcome landmark pricing agreement through Humanitarian Mechanism, urging more manufacturers to follow suit   Médecins Sans Frontières (MSF), Save the Children, UNICEF and the World Health Organization (WHO) welcome the opportunity to make rotavirus vaccine available to more children living in humanitarian crises thanks to a landmark pricing agreement with the manufacturer, GSK. Children living in refugee camps, displaced communities or in other emergency situations now have a better chance of being protected against severe diarrhoeal disease with these lower price rotavirus vaccines. Diarrhoea is one of the leading causes of death among children under five. The agreement makes use of the multi-partner  Humanitarian mechanism, launched in 2017. Ro
Medical Product Alert N°1/2021: Falsified Vitamin A

Medical Product Alert N°1/2021: Falsified Vitamin A

NEWS
Falsified VITAMIN A (retinol) identified in WHO region of Africa   Alert Summary This WHO Medical Product Alert refers to two falsified VITAMIN A (retinol) capsules identified in Chad and reported to WHO in November 2020. Laboratory analysis of recovered samples identified that both products are severely degraded and underdosed – containing less than the stated active ingredient. Both falsified products also carry now-defunct logos – the outdated WHO Essential Drugs Programme logo and the outdated Micronutrient Initiative logo. Both falsified products were supplied at patient level and may still be in circulation in the region. Vitamin A (retinol) is a micronutrient used for the prevention and treatment of vitamin A deficiency. The most severe effects of this deficiency ar
Xeijanz, Xeijanz XR (tofacitinib): Initial Safety Trial Results Find Increased Risk of Serious Heart Related Problems and Cancer With Arthritis and Ulcerative Colitis Medicines

Xeijanz, Xeijanz XR (tofacitinib): Initial Safety Trial Results Find Increased Risk of Serious Heart Related Problems and Cancer With Arthritis and Ulcerative Colitis Medicines

NEWS
  The National Agency for Food and Drug Administration and Control (NAFDAC) has been informed by U.S Food and Drug Administration about an increased risk of serious heart-related problems and cancer in relation to the use of the arthritis and ulcerative colitis medicine Xeijanz, Xeijanz XR (Tofacitinib) compared to another type of medicine called tumor necrosis factor (TNF) inhibitors. FDA required the safety trial, which also investigated other potential risks including blood clots in the lungs and death. Those final result are not yet available. Tofacitinib works by decreasing the activity of the immune system; an overactive immune system contributes to Rheumatoid Arthritis and Psoriatic Arthritis, and ulcerative colitis. It is used for treatment of Rheumatoid Arthritis an
FG, Commissioners Meet Over Sharing of 3.9m COVID-19 Vaccine Doses Today

FG, Commissioners Meet Over Sharing of 3.9m COVID-19 Vaccine Doses Today

NEWS
The Minister of Health, Dr Osagie Ehanire, has convened a meeting with commissioners for health in the 36 states as part of efforts to ensure effective sharing and distribution of the COVID-19 vaccine. The Plateau State Commissioner for Health, Dr Nimkong Lar, and his counterpart in Cross River State, Dr Betta Edu, who disclosed this in separate interviews without correspondent on Wednesday, said the meeting would hold in Abuja on Thursday (today). It was gathered that some commissioners met the Federal Government officials on Wednesday over the distribution of the vaccine. Nigeria on Tuesday received 3.94 million doses of the Oxford-AstraZeneca COVID-19 vaccine, becoming the third African country to benefit from the COVAX facility after Ghana and Ivory Coast. COVAX, an ini...
New WHO Report on Human T-lymphotropic Virus Type 1 Highlights Strategies for its Prevention and Control

New WHO Report on Human T-lymphotropic Virus Type 1 Highlights Strategies for its Prevention and Control

NEWS
  WHO has published a series of products on Human T-lymphotropic virus type 1 (HTLV-1) calling attention to address HTLV-1 through a global public health approach. The HTLV-1 technical report, the HTLV-1 fact sheet and the HTLV-1 meeting report are the products of consultations undertaken by WHO with member states and partners over the past year. HTLV-1 is a retrovirus which causes a chronic lifelong infection in humans. Its transmission happens through breast feeding, sexual contact and blood transfusions and is similar to the HIV virus. It causes a range of clinical syndromes. The commonest of these clinical syndromes are Adult T-cell Leukemia (ATL) and HTLV-1 associated Myelopathy or Total Spastic Paraparesis (HAM/TSP). The current estimates for the total number of people